BioMab, Inc. is an immune-based precision medicine company based in Taiwan. Spun-out of Academia Sinica, our current product portfolio focuses on two primary areas of precision medicine: circulating tumor cell (CTC) and companion diagnostics (CDx). The company’s leading product is a Positive CTC Selection Assay, which can detect cancer through a simple blood draw.
CTC is an emerging field that will transform cancer diagnosis and treatment through simple blood draw (“Liquid Biopsy”). The traditional cancer diagnosis involve surgical biopsy and CT scan, which are not only highly invasive, costly, and harmful to patients, but they can only detect cancers at later stage when it is already too late. CTC can be used regularly to monitor cancer survivors to prevent cancer recurrence, and it can also potentially provide a faster and cheaper way for early screening to help eliminate cancers before they start spreading.
Our second area of focus is immune-based companion diagnostics for use in conjunction with targeted therapies, such as antibody drugs, antibody drug conjugates (ADCs) and immunotherapies. BioMab, Inc. is developing a series of immune-based companion diagnostics and proprietary algorithms to facilitate new drugs/therapeutics development companies to maximize the clinical trial success rates for their new drug candidates.
Website : www.biomabinc.com
Anti-Human Primary Antibody